Physician researcher Ralph Weissleder serves as Director of the MGH Center for Systems Biology. He has been a driving force in the development of novel imaging tools and their application to understanding complex diseases. He has developed systematic ways to explore disease biology using library approaches and has been instrumental in translating several discoveries into new drugs.
Mikael Pittet , PhD, is Associate Professor at Harvard Medical School and Assistant in Cell Biology at Massachusetts General Hospital. He studies network dynamics and regulation of T cell and monocyte responses in complex in vivo environments, and employs various three-dimensional bioimaging technologies to analyze cellular networks and their role in health and disease.
Sylvie Breton is a PhD in Biophysics who specializes in the cell biology of membrane transport, using a multidisciplinary approach including high-resolution laser scanning confocal microscopy, 3D reconstructions of single cells, and electrophysiological techniques. She studies luminal acidification, and water and solute transport in the male reproductive tract. She became Professor of Medicine at Harvard Medical School in 2012 and Assistant Biologist at the Massachusetts General Hospital in 2006, and she has been at MGH since 1994.
Matthias Nahrendorf MD PhD, is a Professor of Radiology at Harvard Medical School. He is the director of the Mouse Imaging Program at CSB, a large-scale imaging resource that offers all major modalities. He focuses on imaging of molecular processes in heart failure, atherosclerosis and transplant rejection. Imaging targets are enzymes, immune cells and molecular players with a central role in cardiovascular disease. The Nahrendorf laboratory uses the entire spectrum of modalities, including MR, nuclear, optical and hybrid imaging, to gain insight into inflammation and tissue repair at a systems level, and in an undisturbed in vivo environment.
Hakho Lee, PhD is a biomedical researcher and engineer. Trained in physics, Dr. Lee focuses on advancing new biosensors by integrating ideas and techniques embodied in biophysics, microelectronics, and nanotechnology. His research also seeks to apply the developed platforms to rigorously and quantitatively analyze living systems, with the ultimate aim of promoting human well-being. Dr. Lee and his team have introduced many new diagnostic technologies that are being actively translated for clinical use. The developed systems include the world’s smallest NMR device, Hall-effect magnetic cytometers, nanaplamonic systems for exosome analysis, and iPhone-based molecular sensors. Dr. Lee serves as the Head of the Cardiovascular Pathology Service at Massachusetts General Hospital. He directs an independent research laboratory studying basic mechanisms of vascular disease. He also overseas the clinical Cardiovascular Pathology Service at MGH and directs the Cardiovascular Histology Core Facility which providing technical support for cardiovascular research to multiple laboratories in the Boston area.
John Higgins studies the dynamics of human pathophysiologic processes by developing mathematical descriptions of complex human disease phenotypes and how they change over time. The research combines medical insight, dynamic systems theory, and experiments utilizing microfluidics, video processing, flow cytometry, simulation, and large-scale analysis of medical databases.
Dennis Brown is a Ph. D. cell biologist who specializes in the use of state-of-the art fluorescence imaging and electron microscopy techniques to follow and dissect physiologically-relevant membrane protein trafficking events in epithelial and non-epithelial cells. He serves as the Associate Director of the CSB and the Director of the MGH Program in Membrane Biology (PMB) which uses use state of the art technologies in the pursuit of important biological questions at the system level. He became Professor of Medicine at Harvard in 2001 and has been at MGH since 1985.
Miles Miller , PhD is a biologist who studies mechanisms of cell communication and drug action from a quantitative, network-level perspective. Trained in bioengineering, he dissects how systems of mammalian cell signaling and regulation bridge across multiple scales, from the molecular to the whole-body level. His research integrates imaging with other measurements and data-driven computational modeling to study cancer and inflammation. His lab also uses engineered materials such as nanoparticles to probe and control multicellular regulation.
Herbert Y. Lin , MD PhD is a physician researcher who studies the role of the TGF-&beta/BMP signaling pathway in chronic diseases such as chronic kidney disease, hemochromatosis, and anemia of chronic disease. He uses a multidisciplinary approach including biochemistry, cell biology and animal studies. His research has generated novel therapeutic applications for the treatment of these disorders. He is an Associate Professor of Medicine at HMS and MGH since 2007.
Charles P. Lin , PhD is an Associate Professor at the Wellman Center for Photomedicine. The main research focus of our group is to develop minimally invasive optical techniques for in vivo imaging and monitoring of cells and tissues as well as therapeutic applications of lasers.
Filip K. Swirski , PhD is Associate Professor at Harvard Medical School (HMS) and Assistant in Immunology at Massachusetts General Hospital. Trained in immunology, he studies leukocyte flux. His lab utilizes a range of cell, molecular and imaging techniques to elucidate how innate immune cells contribute to cardiovascular disease. He focuses on hematopoiesis and monocyte differentiation.
Bradley E. Bernstein , M.D., Ph.D. is a Professor in Pathology at Massachusetts General Hospital and Harvard Medical School, a Senior Associate Member at the Broad Institute and an Early Career Scientist of the Howard Hughes Medical Institute. Bernstein has pioneered the study of chromatin and epigenetics at a genome-wide scale. His work is notable for the discovery of epigenetic mechanisms in pluripotent stem cells, the systematic identification of enhancer ‘switches’ in the human genome that coincide with DNA sequence variants associated with common diseases, and the characterization of regulatory circuits that underlie certain forms of cancer.